{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T05:09:45Z","timestamp":1788930585674,"version":"build-2803163510"},"reference-count":24,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T00:00:00Z","timestamp":1788912000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Lupus mesenteric vasculitis (LMV) is a rare but potentially life-threatening complication of systemic lupus erythematosus, with reported mortality rates of up to 13.4% despite aggressive immunosuppression. Standard management relies on high-dose glucocorticoids (GCs) combined with cyclophosphamide (CYC) or mycophenolate mofetil (MMF); however, prolonged glucocorticoid dependence and disease recurrence remain significant clinical challenges. Telitacicept, a recombinant transmembrane activator and calcium-modulating cyclophilin ligand interactor (TACI)-Fc fusion protein that simultaneously neutralizes B-lymphocyte stimulator and a proliferation-inducing ligand, has demonstrated efficacy in active SLE, yet evidence for its use in LMV is limited to a single case report. We describe a 27-year-old female with severe, glucocorticoid-dependent LMV complicated by autoimmune hemolytic anemia (AIHA), who received pulse methylprednisolone (MP) and intravenous immunoglobulin (IVIG) for acute induction, followed by telitacicept 160 mg weekly as part of a combination maintenance regimen. After conventional induction, telitacicept was associated with successful prednisone tapering from 60 mg\/day to 10 mg\/day over approximately 6 months without disease flare, accompanied by sustained normalization of hemoglobin and complement levels, and radiological improvement. This case represents the second report of telitacicept for LMV and the first to document sustained resolution of AIHA maintained during telitacicept-containing therapy. The induction with pulse MP followed by telitacicept maintenance and accelerated steroid taper\u201d strategy may offer a promising therapeutic option for refractory LMV warranting further prospective investigation.<\/jats:p>","DOI":"10.3389\/fimmu.2026.1872883","type":"journal-article","created":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T04:45:22Z","timestamp":1788929122000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Sustained clinical stability with telitacicept-containing maintenance therapy following glucocorticoid and IVIG induction for lupus enteritis with autoimmune hemolytic anemia: a case report"],"prefix":"10.3389","volume":"17","author":[{"given":"Jinhui","family":"Tan","sequence":"first","affiliation":[{"name":"Department of Rheumatology and Immunology, People\u2019s Hospital of Longhua, Shenzhen","place":["Shenzhen, Guangdong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hai","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Health Management, People\u2019s Hospital of Longhua, Shenzhen","place":["Shenzhen, Guangdong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linghua","family":"Tan","sequence":"additional","affiliation":[{"name":"Department of Health Management, Jiangmen Wuyi Hospital of Chinese Medicine","place":["Jiangmen, Guangdong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianlong","family":"Zhu","sequence":"additional","affiliation":[{"name":"Department of Pathology, People\u2019s Hospital of Longhua","place":["Shenzhen, Guangdong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,9]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"Itc81","DOI":"10.7326\/aitc202006020","article-title":"Systemic lupus erythematosus","volume":"172","author":"Kiriakidou","year":"2020","journal-title":"Ann Intern Med"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2013.11.005","article-title":"Lupus mesenteric vasculitis: clinical features and associated factors for the recurrence and prognosis of disease","volume":"43","author":"Yuan","year":"2014","journal-title":"Semin Arthritis Rheum"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1186\/1750-1172-8-67","article-title":"Lupus enteritis: from clinical findings to therapeutic management","volume":"8","author":"Janssens","year":"2013","journal-title":"Orphanet J Rare Dis"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/ker410","article-title":"Glucocorticoid use and abuse in SLE","volume":"51","author":"Ruiz-Irastorza","year":"2012","journal-title":"Rheumatol (Oxford)"},{"key":"B5","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1080\/08830185.2016.1276903","article-title":"Targeting BAFF and APRIL in systemic lupus erythematosus and other antibody-associated diseases","volume":"36","author":"Samy","year":"2017","journal-title":"Int Rev Immunol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1080\/08923973.2021.1973493","article-title":"Telitacicept as a BLyS\/APRIL dual inhibitor for autoimmune disease","volume":"43","author":"Shi","year":"2021","journal-title":"Immunopharmacol Immunotoxicol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(10)61354-2","article-title":"Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial","volume":"377","author":"Navarra","year":"2011","journal-title":"Lancet"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-021-01591-1","article-title":"Telitacicept: first approval","volume":"81","author":"Dhillon","year":"2021","journal-title":"Drugs"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2023-224854","article-title":"Telitacicept in patients with active systemic lupus erythematosus: results of a phase 2b, randomised, double-blind, placebo-controlled trial","volume":"83","author":"Wu","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2414719","article-title":"A phase 3 trial of telitacicept for systemic lupus erythematosus","volume":"393","author":"van Vollenhoven","year":"2025","journal-title":"N Engl J Med"},{"key":"B11","doi-asserted-by":"publisher","first-page":"9612033241311330","DOI":"10.1177\/09612033241311330","article-title":"The effectiveness of telitacicept in patients with systemic lupus erythematosus: a retrospective, real-world study","author":"Hu","year":"2025","journal-title":"Lupus"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-024-06992-7","article-title":"Efficacy and safety of telitacicept therapy in systemic lupus erythematosus with hematological involvement","volume":"43","author":"Cheng","year":"2024","journal-title":"Clin Rheumatol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1136\/ard-2023-224762","article-title":"EULAR recommendations for the management of systemic lupus erythematosus: 2023 update","volume":"83","author":"Fanouriakis","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.55563\/clinexprheumatol\/2mc79a","article-title":"Telitacicept in combination with conventional therapy for rapid steroid reduction in lupus mesenteric vasculitis and lupus nephritis: a case report","volume":"44","author":"Wang","year":"2026","journal-title":"Clin Exp Rheumatol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.18030","article-title":"Lupus enteritis: an uncommon presentation of lupus flare","volume":"13","author":"Potera","year":"2021","journal-title":"Cureus"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1113\u201322","DOI":"10.1007\/s10067-025-07348-5","article-title":"Effectiveness and safety of telitacicept in patients with systemic lupus erythematosus: a single center, retrospective, real-world study","volume":"44","author":"Fang","year":"2025","journal-title":"Clin Rheumatol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-207726","article-title":"Definition and initial validation of a lupus low disease activity state (LLDAS)","volume":"75","author":"Franklyn","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"B18","doi-asserted-by":"publisher","first-page":"e000538","DOI":"10.1136\/lupus-2021-000538","article-title":"2021 DORIS definition of remission in SLE: final recommendations from an international task force","volume":"8","author":"van Vollenhoven","year":"2021","journal-title":"Lupus Sci Med"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2022-222487","article-title":"Remission and low disease activity (LDA) prevent damage accrual in patients with systemic lupus erythematosus: results from the Systemic Lupus International Collaborating Clinics (SLICC) inception cohort","volume":"81","author":"Ugarte-Gil","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1177\/09612033251390995","article-title":"Safety and tolerability of combination rituximab and belimumab therapy in systemic lupus erythematosus: a systematic review","volume":"34","author":"Voss","year":"2025","journal-title":"Lupus"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1002\/art.27233","article-title":"Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II\/III systemic lupus erythematosus evaluation of rituximab trial","volume":"62","author":"Merrill","year":"2010","journal-title":"Arthritis Rheum"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1002\/art.34359","article-title":"Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study","volume":"64","author":"Rovin","year":"2012","journal-title":"Arthritis Rheum"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2410965","article-title":"Efficacy and safety of obinutuzumab in active lupus nephritis","volume":"392","author":"Furie","year":"2025","journal-title":"N Engl J Med"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2516150","article-title":"Efficacy and safety of obinutuzumab in active systemic lupus erythematosus","volume":"395","author":"Furie","year":"2026","journal-title":"N Engl J Med"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1872883\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T04:45:38Z","timestamp":1788929138000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1872883\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,9]]},"references-count":24,"alternative-id":["10.3389\/fimmu.2026.1872883"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1872883","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,9]]},"article-number":"1872883"}}